SCHEMBL22200352

SCHEMBL22200352

CC(C)n1c(=O)c(-c2ccc(NSc3ccccc3)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.40
CYP1A2 P05177 12/20 0.38
USP2 O75604 10/20 0.38
CYP3A4 P08684 6/20 0.38
MEN1 O00255 6/20 0.38
KMT2A Q03164 6/20 0.38
CYP2C19 P33261 3/20 0.38
CYP2C9 P11712 3/20 0.38
MTOR P42345 4/20 0.37
MAPK1 P28482 4/20 0.37
ALDH1A1 P00352 8/20 0.37
HSD17B10 Q99714 8/20 0.37
CASP1 P29466 6/20 0.35
CASP7 P55210 6/20 0.35
CYP2D6 P10635 3/20 0.35
TSHR P16473 3/20 0.35
HIF1A Q16665 3/20 0.35
EGFR P00533 1/20 0.34
HPGD P15428 3/20 0.34
CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200598 0.92 ERN1 (0.38) ERN1CYP1A2USP2CYP3A4MEN1
SCHEMBL22200350 0.88 USP2 (0.38) ERN1CYP1A2USP2CYP3A4MEN1
SCHEMBL22200338 0.87 ERN1 (0.41) ERN1CYP1A2USP2CYP3A4MEN1
SCHEMBL22200601 0.86 ERN1 (0.43) ERN1CYP1A2USP2CYP3A4MEN1
SCHEMBL22200356 0.84 ERN1 (0.41) ERN1CYP1A2USP2CYP3A4MEN1
SCHEMBL25035568 0.83 ERN1 (0.45) ERN1CYP1A2USP2CYP3A4MEN1
SCHEMBL22200798 0.83 ERN1 (0.41) ERN1CYP1A2USP2CYP3A4MEN1
SCHEMBL22200353 0.83 ERN1 (0.40) ERN1CYP1A2USP2CYP3A4MEN1
SCHEMBL22200795 0.83 ERN1 (0.40) ERN1CYP1A2USP2CYP3A4MEN1
SCHEMBL22200457 0.83 ERN1 (0.42) ERN1CYP1A2USP2CYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed